The decline of anti-drug antibody titres after discontinuation of anti-TNFs: Implications for predicting re-induction outcome in IBD

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 6, 2012, Pages 714-722

  Ben Horin, S ^a   Mazor, Y ^b   Yanai, H ^a   Ron, Y ^a   Kopylov, U ^a   Yavzori, M ^a   Picard, O ^a   Fudim, E ^a   Maor, Y ^a   Lahat, A ^a   Coscas, D ^a   Eliakim, R ^a   Dotan, I ^a   Chowers, Y ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VSL3;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REMISSION; TREATMENT RESPONSE;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOANTIBODIES; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84857363818     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.04997.x     Document Type: Article

References (24)

1. Vermeire S, Noman M, Van Assche G, et al,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007; 56: 1226-31.
2. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of Infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
3. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2 fragment, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
4. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-Infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of Infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8.
5. Karmiris K, Paintaud G, Noman M, et al,. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-40.
6. Wolbink GJ, Vis M, Lems W, et al,. Development of antiInfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54: 711-5.
7. Gold Y, Somech R, Mandel D, Peled Y, Reif S,. Decreased immune response to hepatitis B eight years after routine vaccination in Israel. Acta Paediatr 2003; 92: 1158-62.
8. But DY, Lai CL, Lim WL, Fung J, Wong DK, Yuen MF,. Twenty-two years follow-up of a prospective randomized trial of hepatitis B vaccines without booster dose in children: final report. Vaccine 2008; 26: 6587-91.
9. Artz AS, Ershler WB, Longo DL,. Pneumococcal vaccination and revaccination of older adults. Clin Microbiol Rev 2003; 16: 308-18.
10. Martín-Pagola A, Ortiz-Paranza L, Bilbao JR, et al,. Two-year follow-up of anti-transglutaminase autoantibodies among celiac children on gluten-free diet: comparison of IgG and IgA. Autoimmunity 2007; 40: 117-21.
11. Midhagen G, Aberg AK, Olcén P, et al,. Antibody levels in adult patients with coeliac disease during gluten-free diet: a rapid initial decrease of clinical importance. J Intern Med 2004; 256: 519-24.
12. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS, Danish Multiple Sclerosis Group. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006; 12: 247-52.
13. Hanauer SB, Wagner CL, Bala M, et al,. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.
14. Rutgeerts P, Feagan BG, Lichtenstein GR, et al,. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
15. Regueiro M, Siemanowski B, Kip KE, Plevy S,. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis 2007; 13: 1093-9.
16. Billioud V, Laharie D, Filippi J, et al,. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011; 17: 152-9.
17. Ben-Horin S, Chowers Y,. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-95.
18. Regueiro M, Schraut W, Baidoo L, et al,. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136: 441-50.
19. Louis E, Vernier-Massouille G, Grimaud JC, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy Is stopped. Gastroenterology 2012; 142: 63-70.
20. Waugh AW, Garg S, Matic K, et al,. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010; 32: 1129-34.
21. Laharie D, Chanteloup E, Chabrun E, et al,. The tolerance and efficacy of a postponed retreatment with infliximab in Crohn's disease primary responders. Aliment Pharmacol Ther 2009; 29: 1240-8.
22. Afif W, Loftus EV, Faubion WA, et al,. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
23. Pariente B, de Chambrun GP, Krysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2011 [Epub ahead of print].
24. Kopylov U, Mazor Y, Yavzori M, et al,. The clinical utility of anti human lambda chain-based ELISA versus double antigen ELISA for the detection of anti-Infliximab antibodies. Inflamm Bowel Dis 2011 [Epub ahead of print].